Professional antigen-presenting cells that initiate T cell responses–the bridge between innate and adaptive immunity.
Effective anti-tumor immunity begins with DCs. Tumor-infiltrating DCs capture dying tumor cells, process their proteins, and present peptides on MHC molecules. Cross-presentation allows DCs to present exogenous antigens on MHC-I, activating cytotoxic CD8+ T cells.
DC migration to tumor-draining lymph nodes brings antigen to T cell zones where priming occurs. The quality of this priming–influenced by checkpoint signaling–determines whether effective anti-tumor T cells are generated.
The Immune System's Teachers: Dendritic cells capture tumor pieces, process them, and present them to T cells. They're essential for starting an anti-tumor immune response.
In Tumors: DCs are often dysfunctional—instead of activating immunity, they may express checkpoint ligands that suppress it.
CTLA-4/CD80Loading... interactions occur during T cell priming in lymphoid tissues. CTLA-4 on T cells competes with CD28 for CD80/CD86 on DCs, dampening T cell activation. Ipilimumab (anti-CTLA-4) enhances priming by blocking this inhibitory signal.
This explains why CTLA-4 blockade has different biology than PD-1 blockade: CTLA-4 acts early (priming) while PD-1 acts late (effector phase in tumors). Combination therapy addresses both stages.
The Connection: DCs express CD80, which can engage CTLA-4 on T cells. Anti-CTLA-4 therapy may work partly by preventing DCs from delivering suppressive signals.
Measurement Opportunity: Understanding whether tumor-associated DCs are actively engaging checkpoints (vs just expressing them) could inform therapeutic strategies.
Applicable Platform: Dendritic cells express checkpoint ligands including CD80 and PD-L1. QF-Pro's validated CTLA-4/CD80 and PD-1/PD-L1 assays can characterize DC-mediated immune suppression in the tumor microenvironment.
Ready to apply: DCs express CD80 and PD-L1. QF-Pro's validated checkpoint assays can characterize DC-mediated immune suppression in tumors.
